Merck & Co Inc's  MRK.N Japan unit and partner Ono Pharmaceutical Co Ltd  have filed with regulators for approval to sell Merck's diabetes treatment Januvia in Japan

Merck & Co Inc's MRK.N Japan unit and partner Ono Pharmaceutical Co Ltd  have filed with regulators for approval to sell Merck's diabetes treatment Januvia in Japan. Januvia was approved for use by itself, with the widely used drug metformin, or with members of another class of diabetes drugs called thiazolidinediones, such as Takeda Pharmaceutical's 4502.T Actos

Merck had received reports that some patients taking Januvia developed serious complications, including a potentially fatal skin condition called Stevens-Johnson Syndrome and serious allergic reactions. But it said no causal link between the drug and the conditions has been established.